Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients.
J Clin Psychiatry
; 51(12): 508-12, 1990 Dec.
Article
em En
| MEDLINE
| ID: mdl-2258364
ABSTRACT
Labetalol, a drug with alpha- and beta-adrenergic receptor blocking effects, was used to attenuate hypertension and tachycardia associated with electroconvulsive therapy (ECT) in a series of 11 elderly patients with refractory depression and cardiovascular disease in a placebo-controlled, double-blind crossover study design. As compared with placebo, labetalol was found to blunt mean arterial pressure (MAP) increase by up to 8.26% (p less than .001), heart rate increased by up to 26.07% (p less than .001), frequency of atrial arrhythmias by up to 100% (p less than .01), and premature ventricular contractions by 41.97%. No untoward side effects were observed, and no effect on treatment outcome was noted. Labetalol appears to be an effective and safe agent to use in decreasing hypertension, tachycardia, and possibly arrhythmias in high-risk medical patients with cardiovascular disease undergoing ECT.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Arritmias Cardíacas
/
Doenças Cardiovasculares
/
Transtorno Depressivo
/
Eletroconvulsoterapia
/
Hipertensão
/
Labetalol
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Clin Psychiatry
Ano de publicação:
1990
Tipo de documento:
Article